Dr Arpan Desai

Arpan has over a decade of experience leading project and platform initiatives in the RNA therapeutics space. He has a track record of creating innovative delivery approaches and progressing LNP-based projects from discovery into the clinic across multiple therapeutic areas. Before joining NanoVation he served as a director at AstraZeneca, where he was been involved in leading projects and platform initiatives related to ASOs, anti-miRNA, mRNA for gene editing, vaccines and protein replacement.

Arpan’s work on understanding how LNPs interact with different tumour cells facilitated the selection of preclinical models to assess LNP performance. This resulted in AZs first LNP based mRNA project progressing to the clinic – MEDI1191 (partnered with Moderna Therapeutics). Making innovative medicines requires collaboration across scientific disciplines. The energy and excitement of the scientists working at Research Complex make it an ideal place for NanoVation to be.